Latest Earnings Results: Q2 '26
Estimated EPS
-$0.14
Reported EPS
-$0.18
Surprise
-24.75%
Estimated Rev
$7.85M
Reported Rev
$4.05M
Surprise
-48.39%
• Reported GAAP EPS of -$0.18 down -50.00% YoY • Reported revenue of $4.05M down -76.29% YoY
Bullish Takeaway
AbCellera Biologics Inc. strengthened its balance sheet with new strategic collaborations while continuing to advance multiple clinical-stage programs toward upcoming data readouts in the second half of 2026.
Bearish Takeaway
AbCellera Biologics Inc. experienced a significant revenue decline, an increased net loss, and a reduction in the total number of partner-led programs with downstream stakes during the second quarter.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.14 | -$0.18 | -24.75% | MISSED |
Q1 '26 | -$0.17 | -$0.14 | 18.33% | BEAT |
Q4 '25 | -$0.13 | -$0.03 | 77.61% | BEAT |
Q3 '25 | -$0.14 | -$0.19 | -36.94% | MISSED |
Q2 '25 | -$0.13 | -$0.12 | 10.56% | BEAT |